CORPORATE PRESENTATION
We invite you to download our corporate presentation to help understand our unique purpose, our current commercial footprint, and our innovative pipeline.
Quarterly Results
Press Releases
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a press release that...
An interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlier detection and management of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD)An interim...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has...
Nebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical worsening in patients with...
The pivotal study of Tyvaso® (treprostinil) Inhalation Solution demonstrated a statistically significant preservation of lung function across all subgroups, as measured by absolute forced vital capacity (FVC), and fewer...
Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next yearSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS...
Events and presentations
06 May 2026
United Therapeutics First Quarter 2026 Financial Results
09:00 AM ET
09 Mar 2026
Leerink Global Healthcare Conference
01:00 PM ET
02 Mar 2026
TD Cowen Health Care Conference
02:30 PM ET
02 Mar 2026
Phase 3 ADVANCE OUTCOMES Clinical Trial Results
08:30 AM ET
25 Feb 2026
United Therapeutics Fourth Quarter and Full Year 2025 Financial Results
09:00 AM ET
12 Jan 2026
44th Annual J.P. Morgan Healthcare Conference
04:30 PM ET